中文

← All funding rounds

Matchpoint Therapeutics

United StatesDrug discoveryWatertown, Massachusetts, United StatesPrivate

Website · matchpointtx.com ↗

Designs covalent small molecules, taken as pills, for autoimmune and inflammatory targets that have been hard to drug. Its ACE platform pairs chemoproteomics with machine learning that guides target choice and compound design.

Disclosed total$250M
Rounds on record3
Latest round$150MSeries B · 2026-10-07
Last stated valuationNone stated
Investors named12
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date20222023202420252026$30M$70M$150M
Closed round

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-10-07Series B
    Round

    $150M

    For: take its lead drug MPT-062, an oral T-cell modulator, to clinical proof of concept, with clinical development to begin in 2027, and advance the rest of the pipeline

    Toward the clinic

    The release gives the closing but not the day it closed, and no valuation. It names Atlas Venture and Access Biotechnology as founding investors and Sanofi Ventures as the Series A lead; all other existing investors also took part.

    Co-lead · Nextech InvestCo-lead · NorwestInvusBB BiotechT1D FundBOLD Longevity GrowthExisting investor · Access BiotechnologyExisting investor · Atlas VentureExisting investor · Sanofi VenturesExisting investor · Digitalis Ventures

    On the deal: Brian Matesic (Principal; joins the board, Norwest, joins the board); Kanishka Pothula (Managing Partner; joins the board, Nextech Invest, joins the board)

    Announced by the company · globenewswire.com ↗On the timeline →

  2. 2022-10-14Series A
    Round

    $70M

    For: advance its proprietary platform and its pipeline of covalent molecules, first in immunology

    Models and platform

    Announced at launch as recently closed. The release says all existing investors joined and names Atlas and Access only as seed co-leads; Sanofi Ventures posts the release.

    Lead · Sanofi VenturesVertex Ventures HCDigitalis VenturesAlexandria Venture InvestmentsExisting investor · Atlas VentureExisting investor · Access Biotechnology

    Announced by the company · sanofiventures.com ↗

  3. 2021-11Seed
    Round

    $30M

    Not stated

    Disclosed in the October 2022 launch release, which gives only the month.

    Co-lead · Atlas VentureCo-lead · Access Biotechnology

    Announced by the company · sanofiventures.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.